Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Park, Keunchil [1 ]
Lin, Chia-Chi [2 ]
Huang, Dennis Chin-Lun [3 ]
Shin, Heather Hye-Jung [4 ]
Bogenrieder, Thomas [5 ]
Tan, Daniel S. -W. [6 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[4] Boehringer Ingelheim Korea, Seoul, South Korea
[5] Boehringer Ingelheim Rcv, Vienna, Austria
[6] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Monoclonal antibody; IGF; Phase; 1; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-100
引用
收藏
页码：S554 / S555
页数：2
相关论文
共 50 条
  • [41] MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC)
    Yip, Po Yee
    Cooper, Wendy
    Mahar, Annabelle
    Kench, James
    Kohonen-Corish, Maija R. J.
    Chatfield, Mark
    Boulghourjian, Alice
    Kennedy, Catherine W.
    Mccaughan, Brian
    Boyer, Michael
    Horvath, Lisa
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S499 - S499
  • [42] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [43] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [44] Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2014, 74 : 207 - 221
  • [45] Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC).
    McKeage, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 389S - 389S
  • [46] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).
    Lynch, TJ
    Lilenbaum, R
    Bonomi, P
    Ansari, R
    Govindan, R
    Janne, PA
    Hanna, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 637S - 637S
  • [47] A PHASE 2 TRIAL OF LINIFANIB TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Tan, E.
    Goss, G. D.
    Salgia, R.
    Besse, B.
    Gandara, D. R.
    Hanna, N.
    Ricker, J. L.
    Qian, J.
    Carlson, D. M.
    Soo, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 139 - 139
  • [48] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC)
    Hanna, N
    Bonomi, P
    Lynch, T
    Ansari, R
    Govindan, R
    Janne, R
    Lilenbaum, R
    LUNG CANCER, 2005, 49 : S38 - S38
  • [49] Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
    Keating, Gillian M.
    DRUGS, 2014, 74 (02) : 207 - 221
  • [50] A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
    Shafique, Michael R.
    Fisher, Terrence L.
    Evans, Elizabeth E.
    Leonard, John E.
    Pastore, Desa Rae E.
    Mallow, Crystal L.
    Smith, Ernest
    Mishra, Vikas
    Schroeder, Andreas
    Chin, Kevin M.
    Beck, Joseph T.
    Baumgart, Megan A.
    Govindan, Ramaswamy
    Gabrail, Nashat Y.
    Spira, Alexander, I
    Seetharamu, Nagashree
    Lou, Yanyan
    Mansfield, Aaron S.
    Sanborn, Rachel E.
    Goldman, Jonathan W.
    Zauderer, Maurice
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3630 - 3640
12345